Pacific Biosciences of California  

(Public, NASDAQ:PACB)   Watch this stock  
Find more results for PACB
9.21
-0.42 (-4.36%)
Feb 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.13 - 9.87
52 week 3.58 - 14.00
Open 9.71
Vol / Avg. 2.29M/2.82M
Mkt cap 770.24M
P/E     -
Div/yield     -
EPS -0.67
Shares 79.98M
Beta 3.03
Inst. own 66%
May 3, 2016
Q1 2016 Pacific Biosciences of California Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 3, 2016
Q4 2015 Pacific Biosciences of California Inc Earnings Call
Feb 2, 2016
Q4 2015 Pacific Biosciences of California Inc Earnings Release
Jan 12, 2016
Pacific Biosciences of California Inc at JPMorgan Healthcare Conference
Dec 2, 2015
Pacific Biosciences of California Inc at ISI Medtools Conference
Dec 1, 2015
Pacific Biosciences of California Inc at Piper Jaffray Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 13.08% -109.19%
Operating margin 18.78% -103.73%
EBITD margin - -96.76%
Return on average assets 7.43% -50.75%
Return on average equity 19.42% -106.60%
Employees 344 -
CDP Score - -

Address

1380 Willow Rd.
MENLO PARK, CA 94025
United States - Map
+1-650-5218000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Pacific Biosciences of California Inc. designs, develops and manufactures the PacBio RS II Sequencing System to help scientists resolve genetically complex problems. Based on the Company's Single Molecule, Real-Time (SMRT) technology, its products enable de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms and find genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA (deoxyribonucleic acid) base modification identification to help characterize epigenetic regulation and DNA damage. SMRT enables single molecule, real-time detection of biological processes. Based on its SMRT technology, the Company introduced the PacBio RS II System to address many of the limitations.

Officers and directors

Michael W. Hunkapiller Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 66
Bio & Compensation  - Reuters
Susan K. Barnes Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Age: 61
Bio & Compensation  - Reuters
Kevin P. Corcoran Senior Vice President - Market Development
Age: 52
Bio & Compensation  - Reuters
Michael Phillips Senior Vice President - Research and Development
Age: 64
Bio & Compensation  - Reuters
William Ericson Lead Independent Director
Age: 56
Bio & Compensation  - Reuters
David Botstein Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Brook H. Byers Ph.D Independent Director
Age: 68
Bio & Compensation  - Reuters
Randy Livingston Independent Director
Age: 61
Bio & Compensation  - Reuters
John F. Milligan Ph.D. Independent Director
Age: 54
Bio & Compensation  - Reuters